

PROGRAM, the 14<sup>th</sup> NORDIC LUNG CANCER SYMPOSIUM, August 25-28, 2022  
Bergen, Norway

#### **THURSDAY August 25<sup>th</sup>**

---

16.30-18.00      **Registration**

---

17.00              **Exhibition opens**

---

18.00-19.00      **Satellite symposium**  
*Novartis*

---

---

19.15-20.15      **Reception**

---

#### **FRIDAY August 26<sup>th</sup>**

---

08.30-09.00      **Welcome, program overview**

---

**Lung cancer diagnosis and screening**  
*Zaigham Saghir (DK)*

09.00-09.20      Who should be screened – implementation issues in Nordic countries  
*Haseem Ashraf (DK, NO)*

09.20-09.40      Biomarkers for early detection of lung cancer  
*Mikael Johansson (SE)*

09.40-10.00      Advances in bronchoscopy  
*Øyvind Ervik (NO)*

10.00-10.20      Results from the Norwegian Lung Cancer Registry  
*Lars Fjellbirkland (NO)*

---

10.20-10.45      **Coffee break, exhibition, posters**

---

**Early stage lung cancer**  
*Antti Jekunen (SF)*

10.45-11.05      Are robots here to stay  
*Rune Eggum (NO)*

11.05-11.25      Pulmonary small nodules at chest CT – What's up?  
*Aija Knuutila (SF)*

11.25-11.45      IO and targeted agents in resectable NSCLC  
*Bjørn Henning Grønberg (NO)*

11.45-12.00      Discussion

---

12.15-13.15      **Satellite symposium**  
*MSD*

---

13.15-14.15	<b>Lunch and exhibition, posters</b>
14.15-15.00	<b>Oral presentations – research</b>
	<b>Locally advanced NSCLC</b> <i>Signe Friesland (SE)</i>
15.00-15.20	SBRT in oligometastatic disease <i>Karin Lindberg (SE)</i>
15.20-15.40	IO in locally advanced NSCLC. Any concerns on pneumonitis? <i>Andreas Hallquist (SE)</i>
15.40-16.00	Surgery after immunotherapy or chemoradiotherapy <i>Rene Petersen (DK)</i>
	<b>Speakers' dinner</b>

## **SATURDAY AUGUST 27<sup>th</sup>**

	<b>Oncogene driven NSCLC</b> <i>Åslaug Helland (NO)</i>
08.30-08.50	Smaller and smaller treatment groups – how to implement diagnosis and treatment? <i>Simon Ekman (SE)</i>
08.50-09.10	Introduction of expensive drugs – how to learn from each other <i>Andreas Hallquist (SE)</i>
09.10-09.30	EGFR – intrinsic and acquired resistance mechanisms <i>Jussi Koivonen (SF)</i>
09.30-09.50	New targets beyond EGFR, ALK and ROS1 <i>Edyta Urbanska (DK)</i>
09.50-10.05	Discussion
10.05-10.45	<b>Coffee, exhibition, posters</b>
10.45-12.00	<b>Satellite symposium</b> <i>Astra Zeneca</i>
12.00-13.00	<b>Lunch and exhibition, posters</b>
	<b>Immuno-oncology</b> <i>Jens Benn Sørensen (DK)</i>
13.00-13.20	PD-L1, tumor mutational burden and other markers for immunotherapy

13.20-13.40	<i>Patrick Micke (SE)</i> Moving from single to doublet IO in NSCLC? <i>Mette Pøhl (DK)</i>
13.40-14.00	Real world data on 1 <sup>st</sup> and 2 <sup>nd</sup> line IO in advanced NSCLC: Danish nationwide experience in 1400 patients <i>Mette Thune Mourizen (DK)</i>
14.00-14.20	Vaccination studies in thoracic oncology <i>Odd Terje Brustugun (NO)</i>
14.20-15.00	<b>Coffee, exhibition, poster viewing with authors present</b>
15.00-16.15	<b>Breakout sessions</b>
	A: <b>Lung cancer screening</b> – Clinical experiences in Nordic countries <i>Haseem Ashraf (DK, NO)</i>
	B: <b>Side effects of targeted therapy and IO</b> <i>Jussi Koivunen (SF)</i>
	C. <b>Clinical and registry research</b> – Possibilities for Nordic collaboration <i>Antti Jekunen (SF), Bjørn Henning Grønberg (NO), Simon Ekman (SE)</i>
	D. <b>Palliative care</b> <i>Reeta Piili (SF), Margrethe Schaufel (NO)</i>
16.15-17.15	<b>Feedback from breakout sessions</b> <i>Led by the chairmen of the sessions</i>
	<b>Conference dinner</b>
<b>SUNDAY, AUGUST 28<sup>th</sup></b>	
	<b>Special topics in lung cancer</b> <i>Eeva-Maja Nieminen (SF)</i>
09.00-09.20	Patient reported outcome (PRO) in relation to lung cancer <i>Rasmus Blechingberg Friis (DK)</i>
09.20-09.40	Palliation in the era of so many treatment possibilities – how to know when to stop? <i>Maria Helde Frankling (DK)</i>
09.40-10.15	<b>Coffee, exhibition, posters</b>
	<b>SCLC and mesothelioma</b> <i>Jens Benn Sørensen (DK)</i>

- 10.15-10.35 SCLC – immunotherapy and other new approaches  
*Marianne Knap (DK)*
- 10.35-10.55 Surgery in SCLC – too often or too seldom?  
*Bengt Bergman (SE)*
- 10.55-11.15 Should we continue to provide PCI in SCLC?  
*Jan Nyman (SE)*
- 11.15-11.35 Where are we moving in malignant mesothelioma?  
*Oscar Grundberg (SE)*
- 11.35-11.55 Updates on the role of surgery in mesothelioma  
*Jesper Ravn (DK)*

---

12.00 **Lunch and adjourn**

---